Zacks Research Lowers Omnicell Q3 Earnings Forecast

Analysts cite lower-than-expected performance for the quarter

Feb. 27, 2026 at 12:06pm

Got story updates? Submit your updates here. ›

Zacks Research, an equity research firm, has decreased its Q3 2026 earnings per share (EPS) estimate for Omnicell, Inc. (NASDAQ:OMCL). The research team now expects the company to earn $0.25 per share for the quarter, down from their previous estimate of $0.29. Zacks Research has a "Strong Sell" rating on Omnicell's stock.

Why it matters

Omnicell is a leading provider of medication management solutions for healthcare facilities. Analysts' earnings forecasts are closely watched by investors as they provide insights into the company's financial performance and future outlook.

The details

Zacks Research analyst Team cited lower-than-expected performance as the reason for the decreased Q3 2026 EPS estimate for Omnicell. The consensus estimate for Omnicell's current full-year earnings is $1.09 per share. Zacks Research also issued estimates for Omnicell's Q4 2026 earnings at $0.28 EPS.

  • Zacks Research issued the updated Q3 2026 EPS estimate on Thursday, February 26th.

The players

Zacks Research

An equity research firm that provides investment research and analysis.

Omnicell, Inc.

A healthcare technology company that specializes in medication management solutions for hospitals, clinics, and pharmacies.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

Investors will be closely monitoring Omnicell's financial performance and any further updates from analysts regarding the company's earnings outlook. The decreased Q3 2026 EPS estimate from Zacks Research highlights the importance of closely following industry research and analysis when evaluating investment opportunities.